论文部分内容阅读
目的分析降钙素联合利塞膦酸钠治疗绝经期女性骨质疏松的效果。方法选取2013年1月-2015年1月在该院接受治疗的260例绝经期女性骨质疏松患者为研究对象。按照随机数字表法将患者分为观察组和对照组,每组各130例。对照组患者接受利塞膦酸钠治疗,观察组患者接受降钙素联合利塞膦酸钠治疗。比较两组患者治疗效果。结果治疗6个月后,两组患者髋关节及腰椎部骨密度均较治疗前显著增加(P<0.05),组间比较差异无统计学意义(P>0.05);两组患者体内TRAP-5b、BAP及25(OH)VD指标含量较治疗前显著改善(P<0.05),组间比较差异无统计学意义(P>0.05);两组患者RDQ评分及SF-36评分较治疗前显著改善(P<0.05),且观察组患者改善情况优于对照组(P<0.05)。结论绝经期女性骨质疏松患者采取降钙素联合利塞膦酸钠治疗,可进一步缓解腰背部疼痛,提高生活质量。
Objective To analyze the effect of calcitonin and risedronate on osteoporosis in menopausal women. Methods From January 2013 to January 2015, 260 patients with osteoporosis in postmenopausal women treated in this hospital were selected as the study objects. The patients were divided into observation group and control group according to the random number table method, 130 cases in each group. Patients in the control group received risedronate sodium, and patients in the observation group received calcitonin plus risedronate sodium. Compare the treatment effect of two groups of patients. Results After 6 months of treatment, the BMD of hip joint and lumbar spine in both groups were significantly increased (P <0.05), and there was no significant difference between the two groups (P> 0.05). The levels of TRAP-5b , BAP and 25 (OH) VD significantly improved compared with before treatment (P <0.05), there was no significant difference between the two groups (P> 0.05); RDQ score and SF-36 score of two groups were significantly improved (P <0.05), and the improvement in observation group was better than that in control group (P <0.05). Conclusions Patients with postmenopausal osteoporosis treated with calcitonin plus risedronate may further relieve back pain and improve quality of life.